Tarceva: Following the Glivec path.
Following closely in the footsteps of the Novartis ‘Glivec’ battle, the validity of Section 3 (d) and the grant of compulsory licences seem the talk of town this time around in the Pharmaceutical industry. Our readers will remember the recent post on the Roche-Cipla Row. Generating interest and raising several eyebrows, CIPLA’s latest move to ask the Court to revoke the 2007 patent granted to Roche’s TARCEVA, again hinges a great deal on the pricing of the drug as well […]
Tarceva: Following the Glivec path. Read More »